Cocaine Intoxication Treatment Market By Treatment Type (Benzodiazepines, Cardiovascular Stabilizers, Antipsychotics, Enzyme-Based Antidotes, and Other Emerging Pharmacotherapies); By Route of Administration (Intravenous, Intramuscular, Oral, and Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies); By Geography, Segment Revenue Estimation and Forecast, 2026–2032

Cocaine Intoxication Treatment Market: Emergency Demand, Fentanyl Co-Exposure, and Antidote Development Shape Commercial Opportunity

The Global Cocaine Intoxication Treatment Market was valued at USD 75 million in 2025 and is projected to reach USD 118.02 million by 2032, growing at a CAGR of 6.69% during the forecast period, according to Strategic Market Research

 

The market remains small relative to the medical burden of cocaine use because treatment still relies mainly on low-cost established medicines for agitation, hypertension, chest pain, seizures, and other acute complications. No FDA-approved therapy directly reverses cocaine overdose, so current spending is spread across emergency medicines, monitoring, intensive care, toxicology, and addiction services.

 

Acute cocaine intoxication and cocaine-use disorder represent separate treatment settings. Emergency care focuses on stabilizing cardiovascular, neurological, respiratory, and temperature-related complications. Longer-term treatment relies mainly on behavioral services and investigational therapies aimed at reducing craving and relapse. The two settings differ in clinical goals, reimbursement, purchasing decisions, and commercial potential.

 

Emergency Demand Is Large, but Dedicated Pharmaceutical Revenue Remains Limited

In the United States, an estimated 392,510 cocaine-related emergency-department visits occurred in 2024. Cocaine was reported in 4.7% of visits captured by the Drug Abuse Warning Network, equivalent to 115 visits per 100,000 people. Adults aged 26–44 and 45–64 accounted for 83.5% of these visits, while the visit rate among men was more than twice that among women. The South represented 46.2% of visits, although the Northeast recorded the highest population-adjusted rate at 231 per 100,000.

SAMHSA found that 70.2% of cocaine-related emergency visits in 2024 involved at least one additional substance. Alcohol, cannabis, fentanyl, and benzodiazepines were frequently reported alongside cocaine, increasing diagnostic uncertainty, observation time, and the need for several interventions.

The United States recorded 29,449 cocaine-involved overdose deaths in 2023. Final CDC data show that this number declined to 21,945 in 2024, with the age-adjusted death rate falling from 8.6 to 6.3 per 100,000. The decline is encouraging, but the 2024 total remained far above the 4,681 cocaine-involved deaths recorded in 2011. Hospitals, emergency medical services, public-health agencies, and poison-control systems therefore continue to operate at a much higher cocaine-related risk level than they did before synthetic opioids became widespread in the illicit supply.

Opioid contamination has materially changed treatment demand. CDC analysis covering January 2021 through June 2024 found that 79.1% of cocaine-involved overdose deaths also involved an opioid. Fentanyl exposure means many patients require naloxone, respiratory support, cardiac monitoring, and treatment for stimulant toxicity during the same episode. A future cocaine antidote would therefore supplement rather than replace opioid-reversal products.

 

Europe Supports Both Acute-Care and Addiction-Treatment Demand

Cocaine was the most frequently reported substance in acute drug-toxicity cases recorded by Euro-DEN Plus sentinel hospitals in 2024. It was involved in 1,374 presentations, representing 26% of all cases reported by the participating hospitals. Approximately 79% of patients were male, and the median age was 33. These figures do not represent every European emergency department, but they show that cocaine has become a major source of acute hospital demand in urban treatment networks.

Cocaine was also involved in 1,133 drug-induced deaths reported by 20 European countries in 2024, equal to 27% of deaths reported by those countries. Most fatalities involved more than one substance. At the same time, around 37,000 people entered specialist treatment for cocaine as their primary problem drug for the first time. Cocaine accounted for 25% of first-time treatment entrants, and the number increased by 39% between 2018 and 2024.

England and Wales recorded 1,279 cocaine-involved deaths in 2024, up 14.4% from 2023 and approximately eleven times the 2011 level. Men accounted for 76.8% of the deaths. This rise contrasts with the U.S. decline in 2024 and shows why country-level surveillance is essential when assessing addressable demand. Regional markets are moving at different speeds, and a reduction in one country does not represent a global fall in treatment need.

 

Australia and Canada Reinforce the Polysubstance Burden

Australia recorded about 4,200 cocaine-related ambulance attendances in 2024, with 69% involving multiple drugs and 68% involving male patients. There were also 1,322 hospitalisations in 2023–24 where cocaine was the principal diagnosis and a further 4,775 hospitalisations where cocaine was listed as an additional diagnosis. The larger secondary-diagnosis figure indicates that cocaine frequently appears within broader cardiovascular, psychiatric, trauma, and substance-use admissions.

Canadian surveillance shows a similar pattern. Between January and June 2024, cocaine was involved in 63% of accidental stimulant-toxicity deaths, while methamphetamine was involved in 55%. The percentages overlap because many deaths involved several substances. Canada’s current policy response combines prevention, harm reduction, treatment, recovery, surveillance, and enforcement, supporting service demand while leaving the pharmaceutical opportunity dependent on the emergence of a specific approved product.

 

Generic Symptom Management Dominates Current Treatment Spending

The absence of an approved cocaine-neutralizing medicine keeps the market centred on supportive care. Benzodiazepines remain the primary pharmacological intervention for severe agitation, seizures, and the hyperadrenergic state caused by stimulant intoxication. Hospitals may also use vasodilators, calcium-channel medicines, selected mixed alpha- and beta-adrenergic blockers, anti-seizure medicines, cooling measures, respiratory support, and cardiovascular monitoring according to the patient’s condition.

Current guidance does not support avoiding all beta-blockers in every case. Earlier concerns centred on worsening vasoconstriction through unopposed alpha-adrenergic activity. ASAM and AAAP generally favour vasodilators for cocaine-related ischemia but permit mixed alpha- and beta-blockers, such as labetalol or carvedilol, in selected patients.

This treatment model limits market value because most medicines are generic, treatment is usually confined to a short emergency episode, and spending is recorded within wider emergency or intensive-care budgets. High clinical volume can therefore coexist with a comparatively small dedicated pharmaceutical market.

A drug-specific antidote could change this structure by creating a premium hospital product category. Adoption would depend on more than lowering cocaine levels in blood. Hospital buyers and payers would expect evidence that treatment reduces cardiovascular instability, intensive-care use, observation time, complications, or overall treatment cost.

 

TNX-1300 Remains the Most Visible Acute Intoxication Program

TNX-1300 from Tonix Pharmaceuticals has been the most visible program designed specifically for acute cocaine intoxication. It is a recombinant, double-mutant cocaine esterase intended to break cocaine down into inactive metabolites. The FDA granted the candidate Breakthrough Therapy designation, and Tonix enrolled the first patient in the Phase II CATALYST study in August 2024. The planned trial compared TNX-1300 plus usual care with usual care alone in approximately 60 emergency-department patients.

Tonix stopped enrolment and terminated CATALYST in 2025 because recruitment was slower than expected. The company stated that the decision was unrelated to safety or efficacy and later considered alternative study designs and endpoints.

Eligible patients must be identified during a short emergency window, exposure confirmed, consent addressed, and treatment administered while standard care is underway. Polysubstance exposure further complicates assessment, raising trial costs and delaying development.

TNX-1300 therefore remains a significant proof point, but Breakthrough Therapy designation is not approval and does not establish Phase II efficacy. Its commercial value will depend on whether a workable trial can demonstrate a clinical benefit beyond existing supportive treatment.

 

Engineered Enzymes Could Establish a New Biologic Category

Engineered enzyme therapies represent the clearest scientific route toward directly removing cocaine from circulation. Human butyrylcholinesterase variants and bacterial cocaine esterases are being designed to break down cocaine before additional quantities reach the brain and cardiovascular system. They are often described as biological sponges, although they function more accurately as molecular cleanup agents that repeatedly convert cocaine into less active metabolites.

Research involving engineered butyrylcholinesterase has shown rapid cocaine breakdown and reversal of toxicity in animal models. Earlier work also evaluated albumin-fused cocaine hydrolase candidates, including Albu-CocH1, previously known as TV-1380. These findings support the feasibility of an enzyme-based antidote but do not yet establish a commercially ready treatment.

Manufacturing cost, immunogenicity, dosing, shelf life, emergency use, and real-world performance still require further evaluation. An enzyme therapy may support premium pricing by targeting cocaine directly rather than treating its complications alone. Early use would probably centre on high-volume emergency departments, toxicology units, and hospitals in areas with frequent cocaine-related admissions.

 

EMB-001 and Ketamine Address the Adjacent Use-Disorder Market

EMB-001 should not be described as metyrapone alone. Embera NeuroTherapeutics developed it as a combination of metyrapone and oxazepam for cocaine-use disorder. It is intended to influence stress-related pathways associated with craving and relapse, not to neutralize cocaine during an acute overdose. Embera received an approximately USD 11.1 million NIDA grant to support development, and a Phase II study evaluated EMB-001 in adults with moderate-to-severe cocaine-use disorder.

The program shows how government funding supports an area with limited private investment. Its acute-intoxication relevance is indirect: a successful relapse-prevention medicine could reduce repeat emergency episodes and create outpatient prescription revenue without competing directly with an enzyme antidote.

Ketamine has also been studied as a repurposed treatment for cocaine-use disorder. A 2023 observational study using electronic health-record data reported an association between ketamine exposure and higher remission rates. Earlier small studies suggested potential reductions in craving or cocaine self-administration. These findings remain preliminary and do not make ketamine an approved treatment for either cocaine dependence or intoxication.

 

Behavioral Care Remains Central to Long-Term Treatment

No pharmacotherapy has received FDA approval for stimulant-use disorder. Current clinical guidance identifies contingency management as the behavioral intervention with the strongest evidence, often combined with cognitive behavioural therapy, community reinforcement, or other psychosocial care. Contingency management links incentives to treatment attendance, negative drug tests, or other recovery targets.

Fewer than 10% of addiction-treatment programs covered in the ASAM guideline used contingency management. Financial, regulatory, and staffing barriers create opportunities for specialist providers, managed-care organisations, digital monitoring platforms, testing services, and public-health programs outside the narrow acute-intoxication pharmaceutical segment.

The regulatory pathway for chronic cocaine-use disorder is also different from that for emergency intoxication. FDA guidance for stimulant-use-disorder medicines focuses on sustained reductions in stimulant use and broader clinical improvement. It excludes acute stimulant intoxication, poisoning, and withdrawal, requiring developers of emergency antidotes to use different patient populations, endpoints, and evidence standards.

 

Commercial Risks Will Shape Market Expansion

Polysubstance use is the largest clinical barrier to a cocaine-only product. Patients may arrive with cocaine, fentanyl, alcohol, benzodiazepines, cannabis, or other substances in their system. Even complete cocaine removal may not resolve respiratory depression, alcohol toxicity, trauma, infection, or complications caused by another drug.

Generic competition is another constraint. Benzodiazepines, nitroglycerin, and many cardiovascular medicines used in supportive care are inexpensive and familiar to hospitals. A premium antidote must therefore demonstrate an improvement large enough to justify its acquisition and stocking cost. Reduced cocaine concentration alone may not secure reimbursement without evidence of fewer complications or lower hospital resource use.

Market sizing also remains difficult because current revenue estimates may combine emergency medicines, hospital services, use-disorder treatment, rehabilitation, toxicology, and investigational therapies. The economic burden of cocaine misuse should not be treated as equivalent to pharmaceutical market revenue.

 

Cocaine Intoxication Treatment Market Outlook

Near-term growth will remain linked to emergency visits, fentanyl contamination, polysubstance exposure, rising treatment entries in parts of Europe, and continued investment in addiction services. Generic pricing and the absence of an approved antidote will continue to limit revenue expansion.

The strongest value-creation event would be approval of a medicine that rapidly and safely breaks down cocaine in emergency patients. Such a product could establish a distinct hospital biologics segment, attract public-health funding, and convert part of the current emergency-care burden into separately reimbursed pharmaceutical demand.

An approved antidote would still address only one part of the problem. Opioid co-exposure means hospitals would continue to require naloxone and respiratory support, while long-term relapse prevention would remain dependent on addiction services. Commercially successful products will need to fit existing emergency workflows, work alongside other overdose treatments, remain stable enough for hospital stocking, and demonstrate a reduction in costly complications.

The United States offers the clearest combination of emergency volume, regulatory engagement, public research funding, and active drug development. Europe represents a substantial second opportunity because of rising hospital presentations and first-time treatment entries. Australia, Canada, and the United Kingdom add smaller but strategically relevant markets where cocaine is frequently involved in multi-drug emergencies.

 

Cocaine Intoxication Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 75 Million
Revenue Forecast in 2032	USD 118.02 Million
Overall Growth Rate	CAGR of 6.69% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Route of Administration, By Distribution Channel, By Geography
By Treatment Type	Benzodiazepines, Cardiovascular Stabilizers, Antipsychotics, Enzyme-Based Antidotes, Other Emerging Pharmacotherapies
By Route of Administration	Intravenous, Intramuscular, Oral, Others
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising cocaine-related emergency visits, increasing fentanyl and polysubstance exposure, growing demand for emergency toxicology management, development of enzyme-based cocaine antidotes, expansion of addiction treatment services
Customization Option	Available upon request